Combined [ 223 Ra]Radiumdichloride and [ 177 Lu]Lu-PSMA-617 Therapy in End-stage Metastatic Castration-resistant Prostate Cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41729066.
- Also identified by DOI 10.1097/RLU.0000000000006364 and PMC identifier 13132056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present an advanced mCRPC case treated with combined [ 177 Lu]Lu-PSMA-617 and [ 223 Ra]Radiumdichloride. The regimen was well tolerated, with mild xerostomia, fatigue (CTCAE 1), and moderate anemia (CTCAE 2). Initial imaging and serologic parameters demonstrated a favorable treatment response; however, subsequent evaluations showed progression driven by a dedifferentiated pelvic recurrence, increasingly FDG-avid osseous lesions, and new PSMA-negative lymph node metastases. Early biochemical improvement, including PSA and alkaline phosphatase decline, later transitioned to progression consistent with imaging. This case highlights the feasibility and safety of dual α/β - radionuclide therapy in heavily pretreated mCRPC.
Medical subject headings
- Lutetium
- Dipeptides
- Heterocyclic Compounds, 1-Ring
- Radioisotopes
- Prostatic Neoplasms, Castration-Resistant
- Radium